Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5
Metrics: PDF 2978 views | HTML 4693 views | ?
Waseem Al-Jameel1, Xiaojun Gou2, Shiva S. Forootan1, Majed Saad Al Fayi1, Philip S. Rudland3, Farzad S. Forootan1, Jiacheng Zhang1, Philip A. Cornford1, Syed A. Hussain1, Youqiang Ke1
1Molecular Pathology Laboratory, Department of Molecular and Clinical Cancer Medicine, Liverpool University, Liverpool, L3 9TA, United Kingdom
2Sichuan Antibiotics Industrial Institute, Chengdu University, Chengdu 610081, China
3Department of Biochemistry, Liverpool University, Liverpool, L69 3GA, United Kingdom
Youqiang Ke, email: [email protected]
Keywords: SBFI26, FABP5, CRPC, PPARγ, metastasis
Received: December 19, 2016 Accepted: February 27, 2017 Published: March 09, 2017
Castration resistant-prostate cancer is largely impervious to feather hormonal therapy and hence the outlook for patients is grim. Here we use an approach to attach the recently discovered Achilles heel. The experimental treatment established in this study is based on the recent discovery that it is the FABP5-PPARγ-VEGF signalling axis, rather than the androgen receptor pathway, played a dominant role in promoting the malignant progression of castration resistant prostate cancer cells. Treatments have been established in mice by suppressing the biological activity of FABP5 using a chemical inhibitor SBFI26. The inhibitor significantly suppressed the proliferation, migration, invasiveness and colony formation of PC3-M cells in vitro. It also produced a highly significant suppression of both the metastases and the primary tumours developed from cancer cells implanted orthotopically into the prostate glands of the mice. The inhibitor SBFI26 interferes with the FABP5-PPARγ- signalling pathway at the initial stage of the signal transduction by binding competitively to FABP5 to inhibit cellular fatty acid uptake. This avoids the fatty-acid stimulation of PPARγ and prevents it activating the down-stream regulated cancer-promoting genes. This entirely novel experimental approach to treating castration- resistant prostate cancer is completely different from current treatments that are based on androgen-blockade therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.